Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3
2007

Long-Term Protection from Malaria Linked to Antibodies

Sample size: 217 publication 10 minutes Evidence: high

Author Information

Author(s): Roussilhon Christian, Oeuvray Claude, Müller-Graf Christine, Tall Adama, Rogier Christophe, Trape Jean-François, Theisen Michael, Balde Aissatou, Pérignon Jean-Louis, Druilhe Pierre

Primary Institution: Institut Pasteur, Paris, France

Hypothesis

Is there a relationship between antibody responses to malaria vaccine candidates and clinical protection in humans?

Conclusion

The study found that IgG3 antibodies to merozoite surface protein 3 are strongly associated with clinical protection against malaria.

Supporting Evidence

  • Only IgG3 antibodies to MSP3 were significantly associated with protection against malaria.
  • Children developed protection against malaria when they were very young.
  • Antibodies can be elicited by vaccination early in life.

Takeaway

Kids who have special antibodies can fight off malaria better, and these antibodies can be made through vaccines.

Methodology

The study analyzed antibody responses in relation to malaria protection in a village in Senegal over six years.

Limitations

The findings may not apply to areas with lower malaria transmission rates.

Participant Demographics

The study included 217 participants from Dielmo, Senegal, with 96 children and 121 older adolescents and adults.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI 74.5%–82.0%

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pmed.0040320

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication